kneat.com received a Buy rating and a C$5.75 price target from Stifel Nicolaus analyst Justin Keywood on May 21. The company’s shares closed last Friday at C$5.10.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence
Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, NervGen Pharma, and DRI Healthcare. According to TipRanks, Keywood has an average return of -0.6% and a 52.18% success rate on recommended stocks.
Currently, the analyst consensus on kneat.com is a Strong Buy with an average price target of C$6.10, a 19.61% upside from current levels. In a report released on May 13, CIBC also maintained a Buy rating on the stock with a C$6.25 price target.
Based on kneat.com’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of C$18 million and a GAAP net loss of C$3.95 million. In comparison, last year the company earned a revenue of C$14.75 million and had a net profit of C$2.15 million
